Ublituximab (TG-1101) in combination with umbralisib (TGR-1202) for chronic lymphocytic leukaemia

Ublituximab in combination with umbralisib is under development for the treatment of chronic lymphocytic leukaemia and other types of blood cancers. They both act in different ways to suppress the production and growth of the abnormal lymphocytes caused by bindings to certain cells and proteins in the body that produces the cancer. If licensed, it will offer an additional treatment option for patients with chronic lymphocytic leukaemia.